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Abstract
Background: Cervical cancer represents the third most commonly diagnosed cancer and the fourth leading cause
of cancer-related deaths in women worldwide. Natural killer (NK) cells play an important role in the defense against
viruses, intracellular bacteria and tumors. NKG2D, an activating receptor on NK cells, recognizes MHC class I chain-
related molecules, such as MICA/B and members of the ULBP/RAET1 family. Tumor-derived soluble NKG2D-ligands
have been shown to down-modulate the expression of NKG2D on NK cells. In addition to the down-modulation
induced by soluble NKG2D-ligands, it has recently been described that persistent cell-cell contact can also down-
modulate NKG2D expression. The goal of this study was to determine whether the NKG2D receptor is down-
modulated by cell-cell contact with cervical cancer cells and whether this down-modulation might be associated
with changes in NK cell activity.
Results: We demonstrate that NKG2D expressed on NKL cells is down-modulated by direct cell contact with
cervical cancer cell lines HeLa, SiHa, and C33A, but not with non-tumorigenic keratinocytes (HaCaT). Moreover, this
down-modulation had functional implications. We found expression of NKG2D-ligands in all cervical cancer cell
lines, but the patterns of ligand distribution were different in each cell line. Cervical cancer cell lines co-cultured
with NKL cells or fresh NK cells induced a marked diminution of NKG2D expression on NKL cells. Additionally, the
cytotoxic activity of NKL cells against K562 targets was compromised after co-culture with HeLa and SiHa cells,
while co-culture with C33A increased the cytotoxic activity of the NKL cells.
Conclusions: Our results suggest that differential expression of NKG2D-ligands in cervical cancer cell lines might
be associated with the down-modulation of NKG2D, as well as with changes in the cytotoxic activity of NKL cells
after cell-cell contact with the tumor cells.
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Background
Cervical cancer represents the third most commonly
diagnosed cancer and the fourth leading cause of cancer-
related deaths in women worldwide [1]. Human papillo-
mavirus (HPV) infection is the most important risk factor
for cervical cancer development [2,3]; persistence of
high-risk HPV infection leads to premalignant lesions
and may ultimately lead to cervical cancer in a multistep
process [4,5]. The first line of defense against HPV in
early infection is the innate immune system, which plays
a crucial role in viral clearance [6].
Natural killer (NK) cells are an important arm of the
innate immune system directly involved in the sponta-
neous recognition and lysis of virus-infected and tumor
cells. NK cells are endowed with potent cytotoxic activity,
and they can also produce several cytokines, such as
IFN-g,T N F - a, GM-CSF, IL-5, and IL-8 [7-10]. Evidence is
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immunosurveillance [11].
NK cell activity is finely regulated by an exquisite bal-
ance of inhibitory and activating receptors [12]. One of
the best-characterized activating receptors is NKG2D,
which recognizes two structurally distinct families of
ligands. One of these is composed of MHC class I chain-
related A and B (MICA/B) molecules. The other family
of ligands is composed of the UL16-binding proteins
(ULBPs) 1 to 6, originally identified through interactions
with the human cytomegalovirus glycoprotein UL16
[13,14]. Both families are expressed on a wide range of
epithelial tumors, such as colon carcinoma, breast cancer,
neuroblastoma, and others [13,15-18].
It has been observed that some tumor cells are cap-
able of releasing these regulating ligands. Tumor-
derived soluble NKG2D-ligands have been shown to
down-modulate the expression of NKG2D on NK cells
and T cells, reducing their cytolytic activity [19]. Solu-
ble MICA and soluble isoforms of ULBP2 and ULBP4
have been shown to bind to NKG2D leading to inter-
nalization of the receptor, which favors the develop-
ment of NK cell-acquired dysfunction; soluble MICB
has been shown to bind competitively to NKG2D and
to inhibit the binding of NKG2D to transmembranal
ligands expressed by tumor cells, thus blocking NK cell
activation [19-21].
Recently, it has been shown that not only soluble forms
of ligands are capable of inducing down-modulation of the
NKG2D receptor. Some membrane-bound NKG2D-
ligands, which are secreted via exosomes (such as MICA
and ULBP3), are capable of down-modulating NKG2D
expression on NK cells as well [22,23]. In recent years,
some authors have demonstrated that NKG2D-ligands, by
persistent cell-cell contact, are also able to cause the
down-modulation of NKG2D receptors; however, the
mechanism by which this phenomenon occurs is not yet
clearly known [24-27].
The participation of NKG2D is known to occur in dif-
ferent tumors, such as melanoma, and ovarian, prostate,
and colon carcinomas [26,28-30]. Unfortunately, despite
the high frequency and mortality of cervical cancer
around the world, the participation of the NKG2D recep-
t o ri ne i t h e rt u m o rp r o g r e s s i o no rt u m o re l i m i n a t i o ni n
cervical cancer is not yet fully understood. In this study,
we investigated the expression of ULBP family proteins
(MIC family expression has been already described in a
previous report) in cervical cancer cell lines and the pos-
sible modulation of the NKG2D receptor in a well-estab-
lished NK cell line (NKL), as well as in fresh NK cells.
Likewise, the biological implications of NKG2D/NKG2D-
ligand interaction on NK cell cytotoxic activity were also
evaluated.
Methods
Cell cultures and reagents
Cervical cancer-derived cell lines (HeLa, SiHa, and C33A)
and the spontaneously immortalized, but non-tumori-
genic human epithelial cell line HaCaT (kindly obtained
f r o mD r .P .B o u k a m p ,o ft h eG e r m a nC a n c e rR e s e a r c h
Center, DKFZ, Germany), were maintained in Dulbecco’s
modified Eagle’s medium containing 2 mM L-glutamine
supplemented with 10% fetal bovine serum, penicillin
(100 U/mL) and streptomycin (100 μg/mL) (GIBCO™
Invitrogen Corporation, Carlsbad, CA, USA). The human
NK cell line, NKL (kindly donated by Dr. M. Robertson
of the Indiana University School of Medicine, IN, USA
through Dr. M. Caligiuri of the Ohio State University,
OH, USA) was used to monitor functional changes after
exposing to cervical cancer cells. NKL cells were cultured
in RPMI-1640 medium supplemented with 10% fetal
bovine serum, penicillin (100 U/mL), streptomycin
(100 μg/mL), and 200 U/mL of human recombinant IL-2
(Biolegend, San Diego, CA, USA). This medium has been
referred as complete medium (CM). The human erythro-
myeloblastoid leukemia cell line K562 transfected with
green fluorescent protein (GFP) was also cultured in
RPMI-1640 medium. Cell cultures were maintained at
37°C in a humidified atmosphere containing 5% CO2.
Evaluation of the ULBP family on cervical cancer cell
surfaces
Cell surface expression of different ULBP family proteins
(ULBP1-4) was detected by indirect staining protocol
using a PE-conjugated anti-mouse secondary antibody
after incubation with mouse anti-ULBP1-4 primary anti-
bodies (Santa Cruz Biotech, Santa Cruz, CA, USA). At
least 20,000 events were acquired per experiment using a
FACSAria flow cytometer (BD Biosciences).
Changes in NKG2D expression on NKL cells
In order to assess whether NKG2D expression was
impaired after the contact with tumor cells, we co-cul-
tured NKL cells with each cervical cancer cell line, as
well as with the non-tumorigenic HaCaT cells. Each cell
line was seeded in 6-well plates at a confluence of
approximately 70%. Tumor or HaCaT cells were then co-
cultured with NKL cells at E:T ratio of 1:1 for 1, 2, and
4 h at 37°C. Changes in NKG2D expression, given as
mean fluorescence intensity (MFI), were monitored by
flow cytometry using a PE-conjugated anti-human
NKG2D monoclonal antibody (clone 1D11; Biolegend,
San Diego, CA, USA). At least 20,000 events were
acquired per cell line using a FACSAria flow cytometer
(BD Biosciences). Experiments were performed in tripli-
cate and repeated three times, for a total of nine data
points per sample. Data are expressed as means ± SEM.
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expressed as percentages of increase or decrease with
100% defined as the basal NKG2D expression of NKL
cells cultured alone (control group).
Additionally, we also evaluated changes in NKG2D
expression on fresh NK cells after contact with cervical
cancer cells or HaCaT keratinocytes. Briefly, fresh PBMC
from healthy subjects were obtained on Ficoll-Hypaque
gradients. After isolation, PBMC were adjusted at 1 × 10
6
cells/mL and incubated with anti-CD3-PECy7, anti-CD56-
APC and anti-NKG2D-PE monoclonal antibodies.
Changes in NKG2D expression were determined as
described earlier.
In vitro NKL cytotoxicity assays
To evaluate whether cytotoxic activity of NKL cells was
affected by exposure to cervical cancer cell lines, we co-
cultured NKL cells with the different cervical cancer cell
lines, as well as with the non-tumorigenic HaCaT cells.
HeLa, SiHa, C33A, and HaCaT cells were seeded in
6-well plates at a confluence of around 70% and then
were placed in contact with NKL cells at E:T ratio of 1:1
for 4 h at 37°C. Then, the same NKL cells that had been
co-cultured (or not, in the case of the control group)
with the different cervical cancercell lines were chal-
lenged with GFP transfected-K562 cells in a GFP/propi-
dium iodide (PI) flow cytome t r i ca s s a y[ 3 1 ] .W h e r e
indicated, anti-NKG2D monoclonal antibody (clone
1D11; Biolegend, San Diego, CA, USA) at blocking con-
centration of 30 μg/mL [32] was added to the NKL cells
prior to the cytotoxicity assays.
NKL cells and target cells were incubated at different E:
T ratios (1:1, 5:1, and 10:1) in complete medium for 3 h in
a5 %C O 2 atmosphere at 37°C. Cells were washed twice in
PBS-1% BSA containing 0.1% sodium azide and incubated
in the same buffer plus 20 μL/mL of PI for 15 min at 4°C
in the dark. GFP-transfected K562 cells were incubated
alone to measure basal cell death. At least 10,000 events
were acquired for each sample passed through flow cyt-
ometer. Experiments for NKL cytotoxic activity were per-
formed in triplicate and repeated three times, for a total of
nine data points per sample. Data are expressed as means
± SEM. Analysis of data was performed using the
WinMDI 2.9 software. Cytotoxic activity was expressed as
a percentage of specific lysis and calculated by the follow-
ing formula:
% speciﬁc lysis =
100(% sample lysis − % basal lysis)
100 − % basal lysis
Statistical analysis
Statistical analysis was performed using the GraphPad
Prims 5 software (GraphPad Software,L aJ o l l a ,C A ) .
Data were expressed as percentage and mean median
fluorescence intensity (MFI). Significance was tested by
using one-sample t-Test (theorical mean = 100%) for
NKG2D downmodulation analysis and unpaired t-Test
for cytotoxicity assays. Differences were considered sta-
tistically significant when the p value was < 0.05.
Results
NKG2D-ligands are differentially expressed by cervical
cancer cell lines and non-tumorigenic keratinocytes
Depending on their origin, cancer cell lines may express
different levels of NKG2D-ligands [33]. In this study, we
investigated the expression of ULBP1-4 ligands in cervi-
cal cancer cell lines infected with HPV16 (SiHa), HPV18
(HeLa), HPV-negative (C33A), and non-tumorigenic ker-
atinocytes (HaCaT). While ULBP1 expression was practi-
cally absent in all cell lines, ULBP2 was observed in all
cell lines, being especially high in SiHa and HeLa cells
(Figure 1). ULBP3 was present in HeLa, C33A, and
HaCaT. Conversely, SiHa was totally negative for ULBP3
(Figure 1). Interestingly, ULBP4 expression was only seen
in HaCaT cells (immortalized, although non-tumorigenic
keratinocytes), as also shown in Figure 1. Additionally, in
this study we corroborated our previous report that
MICA expression was higher than MICB expression in
HeLa and SiHa cells. In contrast, MICB was higher in
C33A cells (data not shown) as we had likewise demon-
strated in a previous report [34].
Cervical cancer cell lines down-modulate NKG2D
expression on NKL cells
Some tumors and cancer cell lines are able to modulate
the expression of NKG2D on NK cells and T lymphocytes
after cell-cell contact; this modulation has been shown to
have functional effects [27]. In this study, we investigated
the possible down-modulation of NKG2D on NKL cells
after cell contact with cervical cancer cell lines and non-
tumorigenic HaCaT keratinocytes. NKL cells were co-
cultured with cervical cancer cells and changes in the
expression of NKG2D were evaluated at different time
points. When co-cultured with HaCaT cells, no significant
changes in the expression of NKG2D were observed after
60 min (only 5.02% reduction); this behavior remained
practically the same after 2 and 4 h. In contrast, the co-
culture of NKL cells with cervical cancer cells resulted in
NKG2D down-modulation. After incubation with C33A
cells (which are negative for HPV), the expression of
NKG2D was reduced after 60 min (42.3% reduction) and
continued to decrease over the next two time points
(42.3% and 49.9% reduction at 2 and 4 h, respectively).
T h ec o - c u l t u r eo fN K Lc e l l sw i t hS i H a( H P V 1 6 + )a l s o
showed a strong decrease in the expression of NKG2D
with a diminution of 47.4% during the first 60 min.
NKG2D expression continued to decrease over time
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Page 3 of 10Figure 1 Expression pattern of ULBP1-4 in different cervical cancer cell lines. MFI of the different ULBP proteins in cervical cancer cell lines
and non-tumorigenic HaCaT keratinocytes was measured by flow cytometry using a mouse anti-ULBP1, ULBP2, ULBP3, and ULBP4 primary
antibodies followed by incubation with PE-conjugated anti-mouse secondary antibody (A). Representative flow cytometry histograms for each
cell line are shown in (B). While ULBP1 is practically absent in all cell lines, ULBP2 is expressed universally, with cell surface staining especially
high in SiHa and HeLa cells. ULBP3 expression is moderate in HaCaT, C33A, and HeLa cells, but absent in SiHa cells. ULBP4 expression is seen
solely in the non-tumorigenic HaCaT keratinocytes..
Jimenez-Perez et al. BMC Immunology 2012, 13:7
http://www.biomedcentral.com/1471-2172/13/7
Page 4 of 10(57.9% and 61.7% reduction after 2 and 4 h, respectively).
HeLa (HPV18+) showed similar behavior, although the
effect was less than that observed with SiHa and C33A
(27.4%, 29.4% and 35.2% reduction after 1, 2, and 4 h,
respectively). Notably, the strongest decrease in NKG2D
expression was observed after incubating the NKL cells
with SiHa cells (Figure 2A).
Reinforcing our results with the NKL cells, we also
observed a significant down-modulation of NKG2D on
fresh NK cells after the contact with tumor cells. In
contrast, after contact with HaCaT cells, the expression
of NKG2D remained practically the same (Figure 2B).
Co-culture of NKL cells with different cervical cancer cell
lines modulates cytotoxic activity of NKL cells
Next, we determined whether NKG2D down-modulation
had any effect on the cytotoxic activity of NKL cells.
NKL cells were co-cultured with several cervical cancer
cell lines for 4 h. Following this, NKL cells were removed
and incubated with green fluorescent protein (GFP)-
transfected K562 cells for cytotoxicity assays using flow
cytometry. Gating of the dead tumor cells was based on
the GFP and propidium iodide (PI) double positive popu-
lation. The percentage of specific lysis was calculated as
described in the “Methods” section. When NKL cells
were co-cultured with HaCaT cells, no changes in the
cytotoxic activity were observed (Figure 3). In contrast,
co-cultures with SiHa and HeLa cells, both HPV-positive,
showed a significant reduction in the NKL cytotoxic
activity (Figure 3). Unexpectedly, NKL cells co-cultured
with C33A cells (HPV-negative) showed increased cyto-
toxicity against K562 cells when compared with the con-
trol, non-co-cultured cells (Figure 3). As there is strong
evidence that NK cells participate directly in anti-tumor
immune responses through NKG2D engagement, we
designed blocking experiments using an anti-NKG2D
monoclonal antibody at 30 μg/mL. Results showed that
NKG2D blockage had an additive effect on the cytotoxi-
city diminution. This effect was more evident when NKL
cells were previously incubated with SiHa cells (Figure 4).
Discussion
It is well accepted that NK cells play a key role in the
innate immune system’s surveillance against tumors
[35,36]. Tumor surveillance requires the interaction
between NK cell triggering receptors and their ligands.
NK cells express major histocompatibility complex
(MHC) class I-specific receptors, such as killer cell
immunoglobulin-like receptors (KIRs), which may acti-
vate or inhibit NK-cell effector functions [37]. Inhibitory
KIR receptors allow NK cells to recognize cells that
express self-MHC-I molecules and subsequently inhibit
NK cell effector functions [38]. With the loss of these
inhibitory interactions; however, target cells become
s u s c e p t i b l et oN Kc e l la c t i v i t yv i at h et r i g g e r i n go fN K
cell-activating receptors [39,40]. One of these receptors is
NKG2D, which recognizes two different groups of MHC-
I-like molecules, the MIC and the ULBP/RAET1 families.
These ligands have been found to be expressed in a wide
range of different solid tumors and in some normal tis-
sues [15-18,41]. The recognition of MICs or ULBPs by
NKG2D induces NK cell activation; however, recent stu-
dies have shown that NKG2D-ligands are also capable of
inducing the down-modulation of NKG2D, and subse-
quent loss of NK activation, via persistent cell contact
between NKG2D and NKG2D-ligands [42].
In this study we have shown that cervical cancer cell
lines differentially express both families of NKG2D-
ligands. That is, MICA (data not shown) and ULBP2 are
preferentially expressed by HPV-positive cell lines (HeLa
and SiHa), whereas the HPV-negative cell line, C33A,
preferentially expresses MICB (data not shown). Interest-
ingly, ULBP4 was only expressed by the non-tumorigenic
HaCaT keratinocytes. This differential expression of the
NKG2D-ligands raises the question of whether HPV
infection could play a role in their regulation. Several stu-
dies have shown that some viruses, such as human cyto-
megalovirus and herpesvirus, are capable of modulating
the expression of NKG2D-ligands as an immune evasion
mechanism. Both viruses produce immunoevasins that
target the NKG2D-ligands MICA, MICB, and ULBP1-3.
The intracellular retention of these ligands inhibits their
cell surface expression [43-45]. At this time, it is
unknown whether HPV possesses similar mechanisms
for the evasion of NKG2D-mediated NK responses.
The oncoproteins E6 and E7 of high-risk HPV are cap-
able of interfering with the binding of certain immunopro-
teins, such as transcriptional factors (IRF3, IRF1) involved
in innate immune responses [46-48]. A recent study
showed that the HPV16 E5 oncoprotein intracellularly
binds the CD1 molecule and inhibits its expression in a
HPV16 E5-transfected cervical cancer cell line [49]. This
finding raises the question as to whether HPV-derived
proteins might also be capable of binding other MHC
class I-like molecules, such as NKG2D-ligands. Therefore,
it will be interesting to design co-localization experiments
to determine if any of the HPV oncoproteins could also
intracellularly sequester NKG2D-ligands, leading to func-
tional NK cell and T cell defects.
It has been previously demonstrated that several tumors
expressing NKG2D-ligands induce the down-modulation
of NKG2D on NK cells and T cells. In the present study,
we co-cultured different cervical cancer cell lines and non-
tumorigenic HaCaT keratinocytes with an NK cell line,
NKL, and observed a very strong down-modulation of
NKG2D expression after contact with all cervical cancer
cell lines (SiHa, HeLa, and C33A). Like NKL cells, fresh
NK cells were also susceptible to down-modulate NKG2D
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Figure 2 Down-modulation of NKG2D on NKL cells and fresh NK cells after cellcell contact with cervical cancer cells. NKG2D expression
was evaluated by flow cytometry using a PE-conjugated anti-human NKG2D monoclonal antibody. The variations in the MFI of NKG2D are
expressed as percentages with 100% defined as the basal MFI of NKG2D on NKL cells or fresh NK cells cultured alone (control group). (A) NKL cells
co-cultured with HaCaT cells do not show significant changes in the expression of NKG2D after 60 min; this behavior remains practically the same
after 2 and 4 h. In contrast, the co-culture with cervical cancer cells results in NKG2D downmodulation. After incubation with SiHa (HPV16+) and
HeLa (HPV18+) cells the NKG2D expression is significantly reduced after 60 min and continues to decrease over time. The co-cultures of NKL cells
with C33A cells (which are negative for HPV) show a similar pattern to that observed with SiHa and HeLa. Notably, the strongest decrease in
NKG2D expression is observed after incubating the NKL cells with SiHa cells. Experiments were performed in triplicate and repeated three times, for
a total of nine data points per sample. Data are expressed as mean ± SEM. *p < 0.05. (B) Fresh NK cells significantly down-modulated NKG2D after
the contact with SiHa, HeLa and C33A cells; conversely, after the contact with HaCaT cells, the expression of NKG2D was not modified. Experiments
were performed in duplicate and repeated two times with two different donors. Data are expressed as mean ± SEM. *p < 0.05.
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Page 6 of 10after the contact with tumor cells. This reduction in cell
surface expression of NKG2D is similar to recent reports
showing that this phenomenon can be induced by other
tumor cells [27].
The down-modulation of NKG2D, by binding to either
soluble or transmembranal forms, has been shown to
have functional implications for NK cells and T cells,
leading to impaired NK cell activity and poor cytotoxicity
[21,42]. In this study, we evaluated whether the negative
regulation of NKG2D expression on NKL cells had func-
tional effects on the cytotoxic activity of these cells. We
found that NKL cell cytotoxic activity against target cells
(K562) diminished after contact with the HPV-positive
cervical cancer cell lines, SiHa and HeLa, but not after
contact with HPV-negative C33A cells and non-tumori-
genic HaCaT keratinocytes. Due to the fact that C33A
cells caused NKG2D down-modulation, we would have
expected to find impairments in NK cell activity. How-
ever, co-culture of NKL cells with C33A cells led to
increased cytotoxic activity against K562 cells when com-
pared against both the control and HPV-infected cells.
At this point, it is important to note that C33A cells
expressed a different pattern of NKG2D-ligands than the
other cell lines. Notably, MICA (data not shown) and
ULBP2 were lower than SiHa and HeLa cells, while
MICB levels were higher in C33A cells (data not shown).
A recent study showed that transmembranal MICB is
capable of inducing NK cell activation via the NKG2D
receptor and that this ligand does not participate in nega-
tive modulation of NK cell activity [29]. Thus, it is logical
to speculate that the differences in the patterns of
NKG2D-ligand expression, specifically the higher levels
of MICB, could be responsible for changes in the cyto-
toxicity of the NKL cells against the K562 target cells.
However, we cannot disregard the possible role of soluble
ligand expression. We have recently found that soluble
MICB is also greatly increased in C33A cells compared
with SiHa and HeLa [34].
One important further experiment will be to knock-
down NKG2D expression in NKL cells and to verify
whether the loss of this activating receptor explains the
loss of NKL-mediated cytotoxicity against K562 targets.
This experiment will be important in order to clarify
whether other interactions between the tumor cells and
NKL cells might also be responsible for the loss of cyto-
toxicity observed in our experimental setting.
In order to clarify the role of NKG2D in NKL cyto-
toxic activity, we performed experiments using a
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Figure 3 NKL cell cytotoxic activity is impaired after exposing NKL cells with cervical cancer cells. NKL cells were co-cultured with the
different cell lines for 4 h. Subsequently, the NKL cells were removed from each co-culturing cells (SiHa, HeLa, C33A or HaCaT) and the
cytotoxicity was evaluated. The NKL cells were incubated for 3 h using GFP-transfected K562 as target cells at different E:T ratios (1:1, 5:1, and
10:1) for 3 h. Dead target cells were discriminated based on GFP + and PI + population. The co-culture of NKL with HaCaT cells does not
produce any significant change in NKL cytotoxic activity (A). After co-culture with C33A, we see an increase in the cytotoxic activity of NKL cells
(B). In contrast, co-cultures with SiHa (C) and HeLa cells (D) considerably decrease the cytotoxic activity of NKL cells. Experiments were
performed in triplicate and repeated three times, for a total of nine data points per sample. Data are expressed as mean ± SEM. * p < 0.05, CM:
complete medium.
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Page 7 of 10blocking anti-NKG2D monoclonal antibody. Intrigu-
ingly, the addition of the blocking antibody to NKL cells
previously exposed to SiHa cells resulted in a significant
diminution of the previously observed cytotoxicity. This
could be due to the fact that this cell line is unique
(among the cell lines in this study) in its strong expres-
sion of the NKG2D ligand ULBP2. While the antibody
blockade of NKG2D also significantly inhibited cytotoxi-
city in unexposed and in NKL cells previously exposed
to the other cancer cell lines, this result was not nearly
as marked as the result seen with SiHa pre-exposure.
Certainly, this inhibition was only partial, which indi-
cates that other activating receptors, such as NKp30 or
NKp46 (moderately expressed by our NKL cells) might
also be contributing to the tumor cell lysis or that the
numbers of anti-NKG2D antibody (at the blocking con-
centrations used) were not sufficient to block all the recep-
tors remaining on the cell membrane. In summary, it will
be important to conduct experiments with blocking
antibodies against other important activating receptors,
including NKp30, NKp46, and DNAM-1, which might
lead to tumor cell-NK cell interactions as well.
Conclusions
Taken together, our results suggest that cervical cancer
cell lines expressing NKG2D-ligands induce immunoregu-
lation in NKL cells via down-modulation of NKG2D. This
down-modulation leads to a reduction of the NKL cell
cytotoxic activity against K562 target cells. Thus, these
results indicate that the complexity of tumor immunosup-
pressive mechanisms should be considered before design-
ing NK cell-based therapies in cervical cancer patients.
Abbreviations
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Figure 4 Blocking of the NKG2D receptor on effector NKL cells. NKL cells were co-cultured with the different cell lines for 4 h. The NKL cells
were subsequently removed from co-culturing cells (SiHa, HeLa, C33A or HaCaT) and the NKL cells were additionally incubated with an anti-
NKG2D monoclonal antibody at blocking concentration (30 μg/mL) or with IgG1 isotype control (clone MOPC-21; Biolegend, San Diego, CA,
USA). Afterwards, NKL cells were incubated for 3 h using GFP-transfected K562 as target cells at an E:T ratio of 10:1. Dead target cells were
discriminated based on GFP + and PI + population. The addition of blocking anti-NKG2D monoclonal antibody to the NKL cells had an additive
effect on the previoulsy observed cytotoxicity diminution due to co-culture; this effect was dramatically more evident on NKL cells previously
exposed to SiHa cells. Experiments were performed in duplicate and repeated four times. Data are expressed as mean ± SEM. * p < 0.05.
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